Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Raby

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Drug and Alcohol Dependence|July 19, 2015
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexoneAdam Bisaga, Maria A Sullivan, Andrew Glass, et al.
Drug and Alcohol Dependence|August 28, 2012
Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurementAbigail J Herron, John J Mariani, Martina Pavlicova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinomaH J Mackay, A McInnes, J Paul, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Drug and Alcohol Dependence|July 19, 2015
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexoneAdam Bisaga, Maria A Sullivan, Andrew Glass, et al.
Drug and Alcohol Dependence|August 28, 2012
Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurementAbigail J Herron, John J Mariani, Martina Pavlicova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinomaH J Mackay, A McInnes, J Paul, et al.
Pageof 7